Association between three genetic variants in kallikrein 3 and prostate cancer risk

Background: Epidemiological studies have assessed the association between kallikrein 3 (KLK3) polymorphisms and prostate cancer (PCa) susceptibility. However, published data on this association are somewhat inconclusive. Methods: Articles investigating the association between three KLK3 (rs1058205, rs2735839, and rs266882) variants and PCa susceptibility were searched from online databases, which included 35,838 patients and 36,369 control participants. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to demonstrate the strength of the association. We also utilized ELISA to detect serum expression of KLK3. In addition, in silico tools were adopted to evaluate the relationship of KLK3 expression and PCa survival time. Results: The overall results indicated that polymorphism T>C of rs1058205 was associated with decreased risk of PCa (allele contrast: OR = 0.75, 95% CI = 0.64–0.88, Pheterogeneity < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.42–0.81, Pheterogeneity < 0.001), particularly in Caucasian population (allele contrast: OR = 0.77, 95% CI = 0.65–0.91, Pheterogeneity < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.41–0.82, Pheterogeneity < 0.001). No association was observed between the polymorphism A>G of rs2735839 and risk of PCa. In addition, no association was observed between polymorphism A>G of rs266882 and risk of PCa. Serum KLK3 levels in PCa patients carrying CC/CT genotypes were statistically lower than those carrying TT genotypes. Conclusion: This meta-analysis suggests that rs1058205 polymorphism of KLK3 is a risk factor for PCa development, polymorphism T>C of rs1058205 is associated with decreased susceptibility to PCa particularly in Caucasian population.

[1]  G. Franck Open access , 2012, Cell cycle.

[2]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[3]  M. Spitz,et al.  Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. , 2000, Journal of the National Cancer Institute.

[4]  Jianpeng Hu,et al.  Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer , 2014, Diagnostic Pathology.

[5]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[6]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[7]  J. Witte,et al.  Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11α in Prostate Cancer Risk and Aggressiveness , 2005, Cancer Epidemiology Biomarkers & Prevention.

[8]  A. Tsatsoulis,et al.  Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. , 2003, European journal of endocrinology.

[9]  Z. Szallasi,et al.  CAUSEL: An epigenome and genome editing pipeline for establishing function of non-coding GWAS variants , 2015, Nature Medicine.

[10]  G. Abecasis,et al.  Heritability of Cardiovascular and Personality Traits in 6,148 Sardinians , 2006, PLoS genetics.

[11]  S. Hamilton-Dutoit,et al.  Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma , 2012, Diagnostic Pathology.

[12]  A. Chokkalingam,et al.  Molecular epidemiology of prostate cancer: hormone-related genetic loci. , 2007, Frontiers in bioscience : a journal and virtual library.

[13]  Jack A. Taylor,et al.  Genetic polymorphism and prostate cancer aggressiveness: A case‐only study of 1,536 GWAS and candidate SNPs in African‐Americans and European‐Americans , 2013, The Prostate.

[14]  J. Clements,et al.  Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. , 2010, Endocrine reviews.

[15]  Eleftherios P. Diamandis,et al.  The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.

[16]  Chen Chen,et al.  Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer , 2017, Medicine.

[17]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[18]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[19]  A. Gylfason,et al.  Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels , 2010, Science Translational Medicine.

[20]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[21]  Jianfeng Xu,et al.  Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk‐associated loci , 2015, The Prostate.

[22]  A. Meikle,et al.  Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. , 2000, The Journal of clinical endocrinology and metabolism.

[23]  Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population , 2013, Human Genetics.

[24]  Peter Kraft,et al.  Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. , 2011, Carcinogenesis.

[25]  T. Sellers,et al.  A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. , 2015, Cancer discovery.

[26]  D. English,et al.  Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSA , 2006, Cancer Epidemiology Biomarkers & Prevention.

[27]  J. Carpten,et al.  Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. , 2007, Journal of the National Cancer Institute.

[28]  H. Grönberg,et al.  Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease , 2008, Clinical Cancer Research.

[29]  Liang Sun,et al.  Susceptibility loci associations with prostate cancer risk in northern Chinese men. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[30]  Miltiadis Paliouras,et al.  Human tissue kallikreins: the cancer biomarker family. , 2007, Cancer letters.

[31]  C. P. Morris,et al.  PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. , 2006, Carcinogenesis.

[32]  Linlin Zhang,et al.  rs10505474 and rs7837328 at 8q24 cumulatively confer risk of prostate cancer in Northern Han Chinese. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[33]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  J. Ioannidis Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.

[35]  J. Witte,et al.  Role of Androgen Metabolism Genes CYP 1 B 1 , PSA / KLK 3 , and CYP 11 a in Prostate Cancer Risk and Aggressiveness , 2005 .

[36]  Nilanjan Chatterjee,et al.  Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels , 2011, Human Genetics.

[37]  Tsuguya Fukui,et al.  Systematic Evaluation and Comparison of Statistical Tests for Publication Bias , 2005, Journal of epidemiology.

[38]  F. Hamdy,et al.  Screening for Prostate Cancer , 2006 .

[39]  G. Yousef,et al.  Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. , 1999, Anticancer research.